Company Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
10.68 USD -0.74% Intraday chart for Vir Biotechnology, Inc. -6.32% +6.16%

Business Summary

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its clinical development pipeline consists of product candidates targeting hepatitis B virus (HBV), hepatitis delta virus (HDV) and human immunodeficiency virus (HIV). The Company also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). Its pipeline includes VIR-2218, VIR-3434, VIR-1388, VIR-7229, VIR-2482, VIR-2981, VIR-8190, and VIR-1949. VIR-2218 is an investigational HBV-targeting siRNA. VIR-1388 is an investigational HIV T cell vaccine based on human cytomegalovirus (HCMV).

Number of employees: 587

Sales per Business

USD in Million2022Weight2023Weight Delta
Antibody-based Therapies
100.0 %
1,616 100.0 % 86 100.0 % -94.67%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1,616 100.0 % 86 100.0 % -94.67%

Managers

Managers TitleAgeSince
Chief Executive Officer 56 -
Director of Finance/CFO 53 23-03-26
Chief Tech/Sci/R&D Officer - Nov. 05
Chief Tech/Sci/R&D Officer 54 21-02-28
Chief Tech/Sci/R&D Officer 49 16-11-30
Director/Board Member 75 16-12-31
Investor Relations Contact - Dec. 31
Corporate Officer/Principal - 23-07-09
Corporate Officer/Principal - 17-12-31
Corporate Officer/Principal 73 -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 72 20-07-01
Director/Board Member 59 16-12-31
Director/Board Member 56 16-08-31
Director/Board Member 79 16-12-31
Founder 60 16-04-06
Chairman 75 16-11-30
Director/Board Member 75 16-12-31
Director/Board Member 48 19-08-31
Director/Board Member 65 20-08-27
Chief Executive Officer 56 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 135,032,268 115,298,095 ( 85.39 %) 0 85.39 %

Shareholders

NameEquities%Valuation
SB Investment Advisers (UK) Ltd.
12.36 %
16,684,041 12.36 % 188 M $
BlackRock Advisors LLC
11.73 %
15,835,755 11.73 % 178 M $
ARCH Venture Partners LLC
9.566 %
12,916,663 9.566 % 145 M $
Vanguard Fiduciary Trust Co.
9.107 %
12,297,139 9.107 % 138 M $
GSK PLC
6.333 %
8,550,954 6.333 % 96 M $
6,912,082 5.119 % 78 M $
Baillie Gifford & Co.
2.937 %
3,965,549 2.937 % 45 M $
3,826,548 2.834 % 43 M $
Citadel Securities GP LLC
2.250 %
3,037,948 2.250 % 34 M $
AllianceBernstein LP
2.060 %
2,781,049 2.060 % 31 M $

Company contact information

Vir Biotechnology, Inc.

1800 Owens Street Suite 900

94158, San Francisco

+

http://www.vir.bio
address Vir Biotechnology, Inc.(VIR)